In a keenly observed move, in November 2022, the US Supreme Court agreed to review a controversial case that may have a profound effect on the extent to which pharmaceutical companies must disclose certain information in their patents.
This particular case involves Amgen, Inc., which is fighting to overturn a federal appeals court decision that invalidated a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?